EGFR mutation + MET amplification
|
NSCLC
|
EGFR mutation + MET amplification
|
NSCLC
|
erlotinib Sensitive: C3 – Early Trials
|
erlotinib Sensitive: C3 – Early Trials
|
EGFR mutation + MET amplification
|
NSCLC
|
EGFR mutation + MET amplification
|
NSCLC
|
EGFR inhibitor Resistant: C3 – Early Trials
|
EGFR inhibitor Resistant: C3 – Early Trials
|